Giuseppe Cancello
YOU?
Author Swipe
View article: 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)
108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study) Open
T-DM1 is standard treatment in patients (pts) with HER2-positive breast cancer with residual disease after neoadjuvant therapy. The GIM26-TRASTHER study of the Gruppo Italiano Mammella (GIM) study group collects data from the Italian compa…
View article: Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial Open
Background: Adjuvant chemotherapy for Luminal B-like breast cancers usually includes anthracycline-based regimens. However, some patients are reluctant to receive chemotherapy because of side-effects, especially alopecia, and ask for a “le…
View article: Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials
Systematic review and meta-analysis of post-progression outcomes in ER+/HER2− metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials Open
View article: Management of breast cancer patients during the peak of the COVID 19 pandemic
Management of breast cancer patients during the peak of the COVID 19 pandemic Open
View article: Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy Open
View article: 155P Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients
155P Prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients Open
View article: Evaluation of endocrine therapy and patients preferences in early breast cancer: Results of Elena study
Evaluation of endocrine therapy and patients preferences in early breast cancer: Results of Elena study Open
View article: Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines
Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines Open
View article: Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial
Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial Open
Background: Few data are available on the benefit of metronomic cyclophosphamide, capecitabine, and vinorelbine as first-line therapy in patients with metastatic triple-negative breast cancer. Methods: This phas…
View article: Obituary
Obituary Open
View article: Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy
Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy Open
High TILs levels are significantly associated with a worse TTP in Luminal metastatic BC patients treated by metronomic chemotherapy. Our data confirm the reliability of TILs as a biomarker in the BC metastatic setting. The putative unfavor…
View article: Preventing chemotherapy-induced alopecia by scalp cooling: preliminary data from a study on the efficacy and safety of dignicap® system in breast cancer patients
Preventing chemotherapy-induced alopecia by scalp cooling: preliminary data from a study on the efficacy and safety of dignicap® system in breast cancer patients Open
View article: Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 Open